Evidence map›Paper›PMID 41392239›Full record

ArticleCancer cell international2025

LAMC2 promotes gallbladder carcinoma metastasis through the TGF-β pathway.

Mengyou Xu, Yuanyuan Zhang, Huibo Feng, Taiyu Shang, Yibin Chen, Erdong Liu, Yunkai Lin, Yufei Pan, Yanan Zhou, Xiaofan Feng and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mengyou Xu *Peking University Cancer Hospital, Beijing, China.
Yuanyuan Zhang *National Center for Liver Cancer, Naval Medical University, Shanghai, China.
Huibo Feng *Peking University Cancer Hospital, Beijing, China.
Taiyu ShangNational Center for Liver Cancer, Naval Medical University, Shanghai, China.
Yibin ChenNational Center for Liver Cancer, Naval Medical University, Shanghai, China.
Erdong LiuInstitute of Metabolism & Integrative Biology, Fudan University, Shanghai, China.
Yunkai LinNational Center for Liver Cancer, Naval Medical University, Shanghai, China.
Yufei PanNational Center for Liver Cancer, Naval Medical University, Shanghai, China.
Yanan ZhouDepartment of General Surgery, the 926th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Kaiyuan, China.
Xiaofan FengInternational Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Liwei DongNational Center for Liver Cancer, Naval Medical University, Shanghai, China. dlw@smmu.edu.cn.
Tianyi JiangNational Center for Liver Cancer, Naval Medical University, Shanghai, China. jiantianyi@smmu.edu.cm.
Hongyang WangPeking University Cancer Hospital, Beijing, China. hywangk@vip.sina.com.

Funding

National Natural Science Foundation of China 82373223the Major Clinical Research Projects of Shanghai Hospital Development Center SHDC2020CR2011Athe National Key R&D Program of China 2022YFC2503704the Scientific Research Project of Shanghai Municipal Health Commission 20144Y0266
6 · The paper itself

Abstract

backgroundGallbladder cancer (GBC) is an aggressive malignant tumor that seriously threatens the survival of GBC patients. Laminin-γ2 (LAMC2), an important component of laminins, has been reported to facilitate cancer development and chemoresistance in several cancers. However, the biological effect of LAMC2 on GBC is still unclear.

methodsLAMC2 expression was assessed in GBC specimens through proteomics and RNA-seq data. To evaluate the biological effects of LAMC2, we performed colony formation, sphere formation, wound healing, and transwell and invasion assays, along with an in vivo metastasis model. Additionally, we also explored the role of LAMC2 in GBC organoid. Finally, Western blot and RT-qPCR were employed to identify the molecular mechanism underlying LAMC2-mediated regulation of aggressive behavior in GBC.

resultsHere, we revealed that LAMC2 was overexpressed in GBC tissues and was positively correlated with poor patient outcomes. Furthermore, the genetic silencing of LAMC2 significantly inhibited GBC cell colony formation, sphere formation, and organoid growth. Additionally, LAMC2 deficiency impaired GBC cell metastasis in vitro and in vivo, accompanied by a reversal of the epithelial-mesenchymal transition (EMT) phenotype. Mechanistically, LAMC2 expression was induced by the canonical TGF-β/SMAD2 signaling pathway, and in turn, LAMC2 feedback enhanced the activity of TGF-β signaling by binding to TGF-β receptor II (TGF-βRII).

conclusionOur findings suggest that LAMC2 promotes GBC progression and metastasis, potentially by regulating the TGF-β signaling pathway. Therefore, LAMC2 could serve as a potential prognostic biomarker and therapeutic target for GBC.

Identifiers

PMID41392239
PMCPMC12821298

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.